175 related articles for article (PubMed ID: 28003746)
1. Evaluation of β-cyclodextrin-modified gemini surfactant-based delivery systems in melanoma models.
Michel D; Mohammed-Saeid W; Getson H; Roy C; Poorghorban M; Chitanda JM; Verrall R; Badea I
Int J Nanomedicine; 2016; 11():6703-6712. PubMed ID: 28003746
[TBL] [Abstract][Full Text] [Related]
2. Design and evaluation of cyclodextrin-based delivery systems to incorporate poorly soluble curcumin analogs for the treatment of melanoma.
Michel D; Chitanda JM; Balogh R; Yang P; Singh J; Das U; El-Aneed A; Dimmock J; Verrall R; Badea I
Eur J Pharm Biopharm; 2012 Aug; 81(3):548-56. PubMed ID: 22531300
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the host-guest complex of a curcumin analog with β-cyclodextrin and β-cyclodextrin-gemini surfactant and evaluation of its anticancer activity.
Poorghorban M; Das U; Alaidi O; Chitanda JM; Michel D; Dimmock J; Verrall R; Grochulski P; Badea I
Int J Nanomedicine; 2015; 10():503-15. PubMed ID: 25609956
[TBL] [Abstract][Full Text] [Related]
4. Inclusion Complexes of Melphalan with Gemini-Conjugated β-Cyclodextrin: Physicochemical Properties and Chemotherapeutic Efficacy in In-Vitro Tumor Models.
Mohammed-Saeid W; Karoyo AH; Verrall RE; Wilson LD; Badea I
Pharmaceutics; 2019 Aug; 11(9):. PubMed ID: 31443452
[TBL] [Abstract][Full Text] [Related]
5. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Rajpoot P; Bali V; Pathak K
Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
[TBL] [Abstract][Full Text] [Related]
6. Biodegradable reduction-responsive polymeric micelles for enhanced delivery of melphalan to retinoblastoma cells.
Li J; Wang J; Zhang X; Xia X; Zhang C
Int J Biol Macromol; 2019 Dec; 141():997-1003. PubMed ID: 31521654
[TBL] [Abstract][Full Text] [Related]
7. Rapid and simple flow injection analysis tandem mass spectrometric method for the quantification of melphalan in a lipid-based drug delivery system.
Mohammed-Saeid W; Michel D; Badea I; El-Aneed A
Rapid Commun Mass Spectrom; 2017 Sep; 31(18):1481-1490. PubMed ID: 28667829
[TBL] [Abstract][Full Text] [Related]
8. Solid-State Formation of a Potential Melphalan Delivery Nanosystem Based on β-Cyclodextrin and Silver Nanoparticles.
Sierpe R; Donoso-González O; Lang E; Noyong M; Simon U; Kogan MJ; Yutronic N
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835401
[TBL] [Abstract][Full Text] [Related]
9. Design and Evaluation of Gemini Surfactant-Based Lipoplexes Modified with Cell-Binding Peptide for Targeted Gene Therapy in Melanoma Model.
Mohammed-Saeid W; Soudy R; Tikoo R; Kaur K; Verrall RE; Badea I
J Pharm Pharm Sci; 2018; 21(1):363-375. PubMed ID: 30266136
[TBL] [Abstract][Full Text] [Related]
10. Formulation of temozolomide-loaded nanoparticles and their targeting potential to melanoma cells.
Jiang G; Li R; Tang J; Ma Y; Hou X; Yang C; Guo W; Xin Y; Liu Y
Oncol Rep; 2017 Feb; 37(2):995-1001. PubMed ID: 28035395
[TBL] [Abstract][Full Text] [Related]
11. Quaternary ammonium beta-cyclodextrin nanoparticles for enhancing doxorubicin permeability across the in vitro blood-brain barrier.
Gil ES; Li J; Xiao H; Lowe TL
Biomacromolecules; 2009 Mar; 10(3):505-16. PubMed ID: 19216528
[TBL] [Abstract][Full Text] [Related]
12. Design and Evaluation of RGD-Modified Gemini Surfactant-Based Lipoplexes for Targeted Gene Therapy in Melanoma Model.
Mohammed-Saeid W; Chitanda J; Al-Dulaymi M; Verrall R; Badea I
Pharm Res; 2017 Sep; 34(9):1886-1896. PubMed ID: 28643235
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.
Cirpanli Y; Bilensoy E; Lale Doğan A; Caliş S
Eur J Pharm Biopharm; 2009 Sep; 73(1):82-9. PubMed ID: 19442723
[TBL] [Abstract][Full Text] [Related]
14. A 1H NMR Study of Host/Guest Supramolecular Complexes of a Curcumin Analogue with β-Cyclodextrin and a β-Cyclodextrin-Conjugated Gemini Surfactant.
Poorghorban M; Karoyo AH; Grochulski P; Verrall RE; Wilson LD; Badea I
Mol Pharm; 2015 Aug; 12(8):2993-3006. PubMed ID: 26083126
[TBL] [Abstract][Full Text] [Related]
15. Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.
Peyrode C; Weber V; David E; Vidal A; Auzeloux P; Communal Y; Dauplat MM; Besse S; Gouin F; Heymann D; Chezal JM; Rédini F; Miot-Noirault E
Invest New Drugs; 2012 Aug; 30(4):1782-90. PubMed ID: 21499733
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cellular uptake and intracellular trafficking as determining factors of gene expression for amino acid-substituted gemini surfactant-based DNA nanoparticles.
Singh J; Michel D; Chitanda JM; Verrall RE; Badea I
J Nanobiotechnology; 2012 Feb; 10():7. PubMed ID: 22296763
[TBL] [Abstract][Full Text] [Related]
17. 2-Hydroxypropyl-β-cyclodextrin-modified SLN of paclitaxel for overcoming p-glycoprotein function in multidrug-resistant breast cancer cells.
Baek JS; Cho CW
J Pharm Pharmacol; 2013 Jan; 65(1):72-8. PubMed ID: 23215690
[TBL] [Abstract][Full Text] [Related]
18. A novel lactoferrin-modified β-cyclodextrin nanocarrier for brain-targeting drug delivery.
Ye Y; Sun Y; Zhao H; Lan M; Gao F; Song C; Lou K; Li H; Wang W
Int J Pharm; 2013 Dec; 458(1):110-7. PubMed ID: 24126038
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine nanoparticle topical delivery system for the treatment of melanoma.
Hafeez A; Kazmi I
Sci Rep; 2017 Nov; 7(1):16517. PubMed ID: 29184162
[TBL] [Abstract][Full Text] [Related]
20.
Makhlouf A; Hajdu I; Hartimath SV; Alizadeh E; Wharton K; Wasan KM; Badea I; Fonge H
Mol Pharm; 2019 Feb; 16(2):542-551. PubMed ID: 30605337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
